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The population pharmacokinetics of theophylline were evaluated using 391 theophylline serum 
concentration measurements from 108 neonates and young infants (postnatal age 0-26 weeks), 
who received theophylline for the treatment of  neonatal apnea. A one-compartment pharmacokinetic 
model with first-order elimination was used, with intravenous aminophylline and oral theophylline 
administration modeled as zero-order infusions, The effect of a variety of developmental and 
demographic factors on clearance (CL) and volume (V) were investigated. Hypothesis testing to 
evaluate potentially significant factors produced a final model in which clearance was based on 
weight (kg) raised to an exponential power and postnatal age (weeks), with CL (ml/hr)= 17.5 
(weight) 1.2s 4-1.17 (postnatal age). Clearance was reduced by 12 % for patients receiving parenteral 
nutrition. Volume of distribution in this population was adequately described using only weight, 
with V (L)= 0.858 L/kg. Bioavailability of orally administered drug was not significantly less 
than unity. Interindividual variability in clearance was modest, with a coefficient of variation for 
clearance of  16%. An estimate of interindividual variability in volume could not be obtained. As 
a measure of  residual variability in theophylline serum concentrations, the coefficients of variation 
for theophylline serum concentrations of 5.0, 10.0, and 13.0 mg/L were found to be approximately, 
25, 12, and 9%, respectively. The identification of  influential patient factors and the quantification 
of their influence on theophylline disposition allow for a priori estimates of theophylline phar- 
macokinetic parameters in these patients. 
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INTRODUCTION 
Neonatal apnea is observed in approximately 25% of newborns with 
birth weights less than 2.5 kg (1). Apneic episodes are often associated 
with hypoxia and bradycardia, and are considered a significant factor 
for morbidity and mortality in this patient population (2). Current 
approaches to management of neonatal apnea include appropriate treat- 
ment of predisposing conditions and administration of theophylline or 
caffeine (3-5). 
The range of effective theophylline serum concentrations for the treat- 
ment of neonatal apnea is relatively narrow and generally accepted to be 
between 5 and 15/zg/mL (6). Signs and symptoms of minor theophylline 
toxicity have been observed at the higher concentrations with more serious 
central nervous system and cardiac toxicity appearing as serum concentra- 
tions exceed 20 t x g / m L  (7,8). The relatively narrow therapeutic window for 
theophylline in the treatment of neonatal apnea and the serious side effects 
associated with elevated theophylline serum concentrations in this popula- 
tion have prompted interest in designing dosing regimens to achieve optimal 
therapeutic serum concentrations. 
Several studies have been performed to determine the pharmacokinetics 
of theophylline in the neonate and young infant for use in dosing regimen 
design. However, ethical issues of drug research in this group, e.g., risks 
associated with multiple phlebotomies and problems concerning informed 
consent, have limited the scope of these studies. Table I lists the details of 
major pharmacokinetic studies oftheophylline in the newborn (9-17). These 
studies suggest that clearance in the newborn is much lower than in adults, 
particularly in the very premature neonate, while the volume of distribution 
tends to be higher in neonates than in adults. These studies also suggest a 
substantial degree of unexplained interindividual variability in theophylline 
pharmacokinetics, particularly with regard to clearance. 
Unfortunately, the large degree of variability in theophylline phar- 
macokinetics observed makes it difficult to predict a priori the optimal 
dosing regimen for an individual neonate. In particular, one would like to 
have an understanding of the influence of developmental factors (such as 
weight, postnatal age, etc.) and frequently observed patient variables on 
theophylline disposition (18,19). Sheiner et al. (20) have proposed a method 
for estimating pharmacokinetic parameters and the influence of patient 
variables on these parameters utilizing routinely available clinical data. The 
use of this approach in the neonatal population is particularly attractive 
since it does not require the patient to undergo the rigors of a traditional 
experimental protocol. This paper describes the results obtained by using 
this approach to analyze data collected from neonates and young infants 
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METHODS 
Patients 
Between 1982 and 1985, routine clinical data from 108 neonates 
and young infants receiving theophylline in the University of Michigan 
Hospital's Holden Neonatal Intensive Care Unit, and subsequently seen as 
outpatients in the Pediatric Clinic, were collected by a clinical phar- 
macokineticist providing a pharmacokinetic consult service. All patients 
less than 6 months of age who received theophylline for the prevention or 
treatment of neonatal apnea and had theophylline serum concentrations 
measured were eligible for inclusion in this study. 
Table II. Patient Demographic Data 
Theophylline serum concentrations measurements 
Total no. 391 
Mean concentration (range) 7.0 (0.7-16.3) 
No. of patients 108 
No. of levels per patient 
Mean (range) 3.6 (1-12) 
Birth weight (kg) 
Mean (range) 1.5 (0.6-4.2) 
Gestational age (weeks) a 
Mean (range) 31 (24-42) 
Weight at last theophylline level (kg) 
Mean (range) 3.8 (0.8-7.6) 
Postnatal age at last theophylline level (weeks) 
Mean (range) 8.4 (0.5-26) 
Incidence of patient variables 
n % patients % TCM's b 
Gender 
Male 58 54 53 
Female 50 46 47 
Maternal smoking history 
Positive 35 33 33 
Negative 36 33 35 
Indeterminate 37 34 32 
Incidence of birth asphyxia 54 50 54 
Incidence of phenobarbital administration 
during study period 29 27 14 
Nutrition source c 
Parenteral nutrition 43 40 25 
Breast milk 32 30 20 
Formula 67 62 55 
aAs determined by the Batlard et aL method (21). 
bPercentage of total number of theophylline serum concentration measurements available 
where a particular variable was present. 
CPatients may have received multiple sources of nutrition during the study. Nutrition source 
dictated by major source of nutrition at each theophylline dose. 
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The data collected for this study included the theophylline dosing 
history as recorded in the nursing drug administration record for inpatients 
or as recorded by the patient's parent on a outpatient basis, the time of 
blood sampling for theophylline concentrations, and measured theophylline 
serum concentrations. Daily weights were recorded, but because of the 
difficulty encountered in obtaining accurate and reproducible heights in 
these patients, height data were not included. Table II describes the demo- 
graphic characteristics of the patient population studied. 
All blood samples for determination of serum theophylline concentra- 
tions were obtained as part of routine monitoring of theophylline therapy, 
and were not dictated by study protocol. Blood samples were typically 
obtained shortly before a dose, and the method of sampling (umbilical 
catheter, heel stick, or venipuncture) was determined by the nurse at the 
time of phlebotomy. No record of sampling method was maintained. 
Theophylline serum concentrations were determined by the hospital's Drug 
Analysis Laboratory using HPLC (22). The coefficient of variation associ- 
ated with this assay was approximately 4% over the range of theophylline 
concentrations observed in this study. The study protocol was approved by 
the Human Use Committee of the University of Michigan Hospitals. 
Pharmaeokinetic Model 
The concentration time course of theophylline was described using a 
one-compartment model with first-order elimination. Previous studies of 
theophylline disposition have shown that theophylline pharmacokinetics 
are adequately described using this model when serum concentrations are 
below 20/~g/ml (6,23). Oral administration of theophylline syrup and 
intravenous infusions of aminophylline were modeled as zero-order input. 
Drug absorption following oral administration was assumed to peak at 1 hr 
postdose. Explicit modeling of the absorption process following oral 
administration was not possible due to a lack of theophylline serum con- 
centrations obtained during the absorption phase. Intravenous doses were 
administered by a retrograde technique, and drug delivery was assumed to 
be constant over a 20-rain period (24). 
The pharmacokinetic model was written in a recursive form as described 
previously (20). The recursive model for non-steady-state dosing is 
Cij- Fij" Sij" D~ [1 -exp  {-(CLij / Vij). TPij}] 
CLij 
• exp [-(CLij / Vij ) 9 (At - TPij)] + ~'~i-l,j 
x exp [-(CLiJ Vii)- At] (1) 
where ~'ij is the i th serum concentration of theophylline predicted in the 
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jth individual at time ti, C i - l . j  is the previously predicted serum concentration 
at time ti-l(ti> t i - l ) ,  and At is equal to t i - ti_ 1 . Fij is bioavailability for the 
i th dosage form administered to the jth patient, equalling unity for parenteral 
doses and calculated as a regression parameter for oral doses. Sij is the salt 
factor for the i th dosage form in the jth patient, equalling 0.85 for aminophyl- 
line doses and unity for theophylline doses. Doseij is the amount of the i th 
dose (mg) in the jth patient, TPij is the time to peak following the i th oral 
dose or the duration of the infusion for the i th intravenous dose in the jth 
patient, with a value of 1.0 and 0.33 hr, respectively. Individuals may have 
received oral and/or  intravenous dosing during the course of theophylline 
therapy. CLij and V~ are the i th total clearance and volume of distribution 
for theophylline in t h e  jth individual. Using the recursive form of the model, 
the solution is updated for each successive event (dose or calculation of 
theophylline serum concentration) in chronological order using the currently 
predicted values for CLij and V~j. 
Patients receiving a constant dosing regimen (dosage and dosing inter- 
val) for 4 days or longer were assumed to be at a steady state condition, 
and the pharmacokinetic model was modified so that the serum concentra- 
A 
tion of theophylline (Cssij) obtained at time ti during a steady state dosing 
regimen was calculated as 
~ssi j = [ Fij. S i j "  ( Doseij / TPij)/CLij ] ' [ 1 - exp { -  ( CLij / Vij ) 9 TPij}] 
[1 - e x p  {-(~'~'iff Vii)" ~'ij}] 
x exp [-(CLiff Vii)" (tij - TPij)] (2) 
where Fij, S~jDos%, TPij, CLij, V~j, and tij are as defined above, and z~j is 
the steady state dosing interval (hr) for the i th steady-state dose in the jth 
patient. 
Initial Regression Models for Clearance and Volume 
In the initial regression model, clearance was based on the patient's 
weight raised to an exponential factor, and was modeled to increase in an 
additive fashion with increasing postnatal age, as suggested by Lonnerham 
et al. (16). The effects of other patient variables on clearance were also 
included in the model as seen in Eq. (3). Because the data were composed 
of primarily steady state concentrations, with relatively little information 
regarding volume of distribution, only the effect of patient weight and 
postnatal age on volume were explored as seen in Eq. (4). 
0 cl cl CLij = (0Cwll ' WTijw.2+ 0 a 9 AGEij ) 9 0 p  . . . .  teral nutrition 
X 0 b r e a s t  milk " 0 p h e n o b a r b i t a l  " 0 f e m a l e  g e n d e r  " 0 l o w  ges ta t iona l  age  
X 0 a s p h y x i  a 9 0 m a  t . . . .  1 smok ing  " 0 c o m p l i  . . . .  ( 3 )  
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0 female gender 




Current primary source of patient's nutrition is parenteral nutrition. 
Current primary source of patient's nutrition is breast milk. 
Patient must be currently receiving phenobarbital, or have received 
phenobarbital in the past 5 days. 
Patient must be female. 
Patient must have a gestational age of -<30 weeks. 
Patient must have at least one of the following: (i) Frank cyanosis at 
birth requiring emergent intubation; (ii) first arterial blood pH of -<7.2; 
(iii) a 1- or 5-minute Apgar score of -<3. 
Patient is born to mother with a documented positive smoking history. 
Patient must currently be an outpatient. 
Vii = OvA . WTi~ :'2 + OVa . AGEi j  (4) 
where  CL""ij and Vii represent  the i th predic ted  theophyl l ine  c learance ( m L / h r )  
and  vo lume  o f  distr ibution (L) for  the jth individual .  The 0C~'s and 0V's are 
compu ted  regression pa ramete r s  relating the jth pat ient ' s  weight  in k i lograms 
(WT~j) and postnata l  age in weeks (AGEij )  at the t ime of  a theophyl l ine  
dose or sampl ing  for  a theophyl l ine  serum concent ra t ion  to the predic ted  
theophyl l ine  c learance and  volume,  respectively.  The  remaining  0's rep- 
resent the fract ional  increase or  decrease in theophyl l ine  c learance associ- 
ated with the presence  of  var ious pat ient  variables.  When  a var iable  is 
absent  in an individual ,  the 0 is assigned a value o f  1. In 34% of  patients,  
the materna l  smoking  history could not be  ascertained.  In these cases the 
data  were fit twice: once by  assuming the pat ients  were born  to nonsmok ing  
mothers  and once by including only those pat ients  with a known posi t ive 
or negative exposure.  The criteria for  these var iables  are given in Table  I I I .  
S t a t i s t i c a l  M o d e l  
The persistent  r a n d o m  individual  deviat ions in c learance and vo lume  
f rom the values predic ted  by the regression formulas  were mode led  using 
Eqs. (5) and  (6), respectively.  
In CLij = In ~"Lij + r/~ l (5) 
In Vii : In ~i  + r/~ (6) 
where In CL"~j and In ~j  are the natural  logar i thm of  the values of  c learance 
and  vo lume  predicted for  the jth individual  by Eqs. (3) and  (4), In CLij and 
In V~j are the natural  logar i thms of  the jth individual ' s  (unknown)  true 
pha rmacok ine t i c  parameters ,  the ones used in equat ions (1) and  (2), and  
~7~ ~ and r/j' are normal ly  distr ibuted r a n d o m  errors that  represent  the 
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difference between the jth patient's true parameters and the values predicted 
by the regression models. The rl~ 1 and ~7~ are assumed to be independent, 
identically distributed statistical errors with mean zero and variances w~j 
2 and o)v, respectively. The variances of rt~ ~ and 7/1' j across the patient popula- 
tion are the population variances of the "true" clearance and volume about 
their respective predicted values (20). The use of Eqs. (5) and (6) to model 
the variance of clearance and volume implies that the interindividual varia- 
bility increases with increasing clearance and volume. Also, when o92 is 
small, the square root of the variance of clearance and volume approximates 
the coefficients of variation of the respective parameter (25). 
Residual variability, describing the random deviation of the i th observed 
theophylline concentration in the jth individual from the "true" concentra- 
tion given by Eq. (1) or (2), was modeled as 
A 
C~j = C~j + e~j, (7) 
where C~j is the i th measured theophylline concentration in the jth patient 
and Cij is the corresponding theophylline serum concentration from Eq. 
(1) or (2), as appropriate. The eaj are assumed to be independent, identically 
distributed statistical errors with mean of zero. The variance for eij, 0-2, was 
modeled as 
0 . 2  = 2 2 ^ 2  0~1 + 0~2" C~j (8) 
where 0~1 and 0~2 are freely estimated variables relating the variance of e~j, 
0.2, to the squared predicted theophylline serum concentration, ~2. The 
use of this model for 0.2 allowed for hypothesis testing regarding the nature 
of this error. In this way, a proportional error model (0~ fixed to 0) could 
be compared to an additive error model (0~2 fixed to 0). In the evaluation 
of the initial regression models for clearance and volume, the general form 
of the model for 02, as described by Eq. (8) was employed. 
Data Analysis 
Data analysis was performed using version II, level I of the NONMEM 
program and the PREDPP package (ADVAN 1, TRANS 2, SS 1) (25,26). 
Estimates of the coefficients (0) of the regression formulas, the components 
ofcr 2 (O~land 022), 2 2 tool, wv, and their 95% confidence intervals were sought. 
Evaluating Improvement in Fit 
In fitting the data, NONMEM computes the value of a statistic, the 
minimum value of the objective function, which is proportional to minus 
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twice the log likelihood of the data. In preliminary evaluations of various 
demographic factors and patient variables in the initial regression model, 
objective function values were used to evaluate the increase in goodness of 
fit upon inclusion of each parameter. The difference in objective function 
values obtained by comparing a restricted model in which a parameter's 
value is fixed to the null hypothesis value, and a nonrestricted model in 
which the parameter's value is freely estimated, is asymptotically distributed 
as chi-square with 1 degree of freedom (27). In order to identify potentially 
significant factors, a change in objective function of >3.8, associated with 
a p value of ---0.05 was required. Factors that were determined to have a 
potentially significant effect were then included in an intermediate model 
for further hypothesis testing. 
In the evaluation of the intermediate regression model, the objective 
function values were used to evaluate the decrease in goodness of fit obtained 
upon independent deletion of each parameter. This was achieved by alter- 
nately fixing (restricting) each parameter value to the null hypothesis value. 
Because of the multiple tests performed in this analysis, we required a 
change in objective function of >7.9, associated with a p value of ~0.005, 
to indicate statistical significance. The final model included only those 
parameters that proved significant using this more rigorous criterion. An 
overall test of the candidate for the final model was then made by comparing 
its objective function value with that of the intermediate model in which 
all parameters were freely estimated. The difference in the objective function 
values is approximately distributed as chi-square with degrees of freedom 
equal to the difference in the number of parameters between the two models. 
In testing models where one model was not merely a subset of the 
other, e.g., a comparison of the effect of modeling volume with or without 
weight, strict application of the likelihood ratio test was deemed inappropri- 
ate. In this case, the difference in objective functions was evaluated and it 
was assumed that a difference, similar in magnitude to that observed during 
testing of highly significant factors in restricted models, i.e., >7.9, indicated 
that one model was potentially superior to another. 
RESULTS 
The preliminary analyses using the initial regression models for clear- 
ance indicated that gender, low gestational age, birth asphyxia, and maternal 
smoking were not associated with a significant effect on clearance (p > 0.05). 
Moreover, patient compliance in the outpatient setting appears equivalent 
to compliance during inpatient care, given the lack of difference in clearance 
between the two settings in neonates of equivalent age and size. With regard 
to the apparent volume of distribution of theophylline, neither postnatal 
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age nor  the exponent ia l  func t ion  for volume were associated with a sig- 
nificant effect (p > 0.05). The bioavai labi l i ty  of orally adminis tered  theophyl-  
line was not  significantly less than uni ty  (p > 0.05). All of  these evaluat ions  
were associated with a log l ikel ihood difference of <3.8. 
As a result  of  the pre l iminary  analyses, the intermediate  model  for 
theophyl l ine  clearance was based on pat ient  weight raised to a power, with 
factors for patients receiving parenteral  nutr i t ion,  breast  milk feedings,  and  
phenobarb i ta l  adminis t ra t ion  retained. The in termediate  model  for vo lume 
of dis t r ibut ion was based only on pat ient  weight. As seen from Tables IV 
and V, hypothesis  testing of these intermediate  models  suppor ted  a final 
model  in which theophyl l ine  clearance is based on pat ient  weight raised to 
a power, with a factor for patients receiving parenteral  nut r i t ion;  volume 
of dis t r ibut ion is adequate ly  modeled  using a l inear  func t ion  of pat ient  
weight. The final regression formulas for clearance (ml /h r )  and  volume of 
Table IV. Results of Hypotheses Testing of Intermediate Model 
Hypothesized Log 
value of likelihood 
Question addressed parameter difference p Conclusion 
Clearance 
Does the use of a linear 
relationship between weight 
and clearance influence 
clearance ? 
Does the use of an 
exponential relationship 
between weight and 
clearance influence 
clearance? 
Does postnatal age 
influence clearance? 
Do parenteral nutrition 
feedings influence 
clearance? 







Is the intercept term 
important in modeling 
residual variability? 
Is the slope term important 
in modeling residual 
vari ability ? 
0~, 1 = 0 276.9 << 0.0005 Yes 
cl  _ 0w. 2 - 0 40.1 <0.0005 Yes 
c l m  0 a - 0 30.9 <0.0005 Yes 
0 p a r e n t e r a l  n u t r i t i o n  = I 21.4 <0.0005 Yes 
0 b r e a s t  m i l k  = 1 6.3 >0.01 No 
0phenobarbita I = 1 5.5 >0.01 No 
0~ = 0 16.3 <0.0005 Yes 
/9 ~2 = 0 < 1 > 0.30 No 
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Is a model without an effect of weight on volume as good 74.2 
as a model which uses weight? 
Is a model that uses postconceptional age as an age-related 24.3 
factor influencing CL as good as the intermediate model 
in which postnatal age is used? 
Probably not 
Probably not 
distribution (L) are giving by Eqs. (10) and (11). 
CL""ij=(O~,l " WZi~Iz+OCa 1" aGEij)" Op . . . .  t e r a l  n u t r i t i o n  (10)  
A 
Vij = 0Vw,1 " W T i j  ( 1 1 )  
The final estimates (with 95% confidence intervals shown in parentheses) 
of the regression coefficients provided by the NONMEM analysis were: 
0~,1 = 17.5 (15.5-19.5) ml/hr per kg 
cl 0w,2= 1.28 (1.18-1.38) (an exponential term) 
0~ 1= 1.17 (0.643-1.70) ml/hr per week 
0p .... teralnutrition=0"879 (0.816-0.942) (fractional decrease) 
0v1=0.858 (0.793-0.923) L/kg 
Under the final regression formula and parameter estimates described 
above, the estimate of the coefficient of variation for interindividual variabil- 
ity in clearance was 16%, with a 95% confidence interval of 10.4-20.1%. 
The estimate of the coefficient of variation for volume was insignificantly 
small suggesting that all observed interindividual variability is adequately 
explained by the model for interindividual variability in clearance. 
An evaluation of the model for residual variability [see Eq. (8)], 
performed once the final regression models were determined, suggested that 
residual variability was adequately described with a simple additive error 
model. This additive error model for residual variability yields a standard 
deviation of 1.24/xg/ml, with a 95% confidence interval of 1.16-1.31/xg/ml. 
Thus, the coefficient of variation for residual variability in theophylline 
serum concentrations of 5.0, 10.0, and 13.0 ~zg/ml would be approximately 
25, 12, and 9%, respectively. 
In a final check of the overall acceptability of the final regression model 
described in Eqs. (9) and (10), these formulas were compared with the 
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initial fully defined models for clearance, volume, and residual variability. 
In performing this hypothesis test, all parameters in the initial models were 
freely estimated and the following factors were then fixed to their null 
hypothesis values: 0gender, 0low gestational age, 0asphyxia, 0maternal smoking, 
0b . . . .  t milk, 0phenobarbital, 0compli . . . .  f rom the  equation for  c l ea rance  [Eq. (3)]; 
OVa and 0~,2 from the equation for volume [Eq. (4)]; and 0~2 from the 
equation for residual variability [Eq. (8)]. The log likelihood difference for 
these two fits was 12.7, p > 0.2, X 2 distribution with 10 degrees of freedom. 
DISCUSSION 
It is not surprising that the most important variables for predicting 
theophylline clearance in this patient population are weight and postnatal 
age. Each of these factors is related to the stage of development of the 
newborn and thus, the degree of functional activity of drug-eliminating 
organ systems (9). The final regression model for clearance suggests that 
the rate of theophylline clearance increases disproportionately with increas- 
ing weight. Moreover, the further improvement in fit obtained upon the 
inclusion of postnatal age in the model for theophylline clearance indicates 
that an older newborn is expected to have a higher rate of clearance than 
a younger newborn of equal weight. 
Other researchers have attempted to provide insight into predicting 
theophylline clearances in this population by investigating the correlation 
of various developmental factors with clearance. The majority of published 
studies appear to support the results reported herein. Nassif et al. (15) 
showed good correlation between increasing postnatal age and increasing 
theophylline dosage requirement. Lonnerholm et al. (16) showed that 
theophylline clearance (ml/hr per kg) appeared to increase linearly with 
postnatal age. Gilman et aL (17) found that among body weight, postnatal 
age, postconceptional age, and duration of theophylline therapy, postnatal 
age was the most important determinant in theophylline clearance. Bada et 
al. (28) documented higher theophylline concentrations in newborns with 
gestational ages less than 30 weeks relative to more mature babies on 
equivalent mg/kg theophylline doses. 
The strong relationship observed between indices of maturation (such 
as weight and postnatal age) and clearance suggest that similar factors such 
as gestational age should also be important predictors of theophylline 
clearance. The results of this analysis suggest that theophylline clearance 
is adequately described using weight to an exponential power and postnatal 
age, regardless of gestational age. Other investigators have also failed to 
show an influence of gestational age on theophylline clearance (16,19). It 
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should be pointed out, however, that there is a high degree of linear 
correlation between gestational age and birth weight in the neonate (Pear- 
son's correlation coefficient equals 0.72 in our population). Thus, the 
inclusion of weight in our final clearance model captured any differences 
in theophylline clearance in the low gestational age neonate. Finally, though 
postconceptional age has been used to estimate clearance in other studies 
(29), it did not perform as well as postnatal age in our model for theophylline 
clearance. 
In addition to the factors of weight and postnatal age, the only factor 
having a statistically significant influence on the rate of theophylline clear- 
ance in our population was concomitant parenteral nutrition (PN) 
administration. Patients receiving PN had a mean theophylline clearance 
that was 12% lower than those receiving breast milk or oral formula. This 
decrease in theophylline clearance might be expected since high glucose 
intake has been noted to inhibit drug metabolism in animals (30) and the 
administration of PN has been associated with hepatic dysfunction in the 
newborn (31). In a study of the effects of PN on theophylline disposition 
in a group of 17 premature infants, Hilligoss et aL (14) found that the rates 
of theophylline clearance in five patients receiving PN (-17-25 rnl/hr per 
kg) were generally similar to clearance rates observed in 12 young infants 
not receiving PN (~ 16-30 ml/hr  per kg). Interestingly, the gestational age 
and birth weight were significantly lower in the group receiving PN, but 
additional demographic information for the two groups (e.g., postnatal age 
and current weight) was not reported. A graph of individually determined 
theophyl l ine  clearance values (ml/hr pe r  m 2) versus duration of therapy 
included in the publication suggests that among patients who received 
theophylline for a similar duration, those who received PN tended to have 
lower rates of clearance. 
In our study population, PN was typically administered in the early 
weeks of life to the more premature newborns. Because the clinical course 
of such patients is often more complicated than that of more mature 
newborns, it is unclear whether the administration of PN itself or the typical 
clinical status of study patients receiving PN resulted in the observed 
decreased rate of theophylline clearance. In order to explore this further, 
we compared theophylline clearance in patients who had previously received 
PN, but who were currently receiving enteral feedings, with patients who 
had never received PN. Interestingly, once PN administration was discon- 
tinued, the estimated theophylline clearance in these patients when adjusted 
for age and weight did not differ from the estimated clearance for patients 
who had never received PN. These findings imply that it is only during the 
time of PN administration, or concurrent with the clinical situation common 
to patients receiving PN, that theophylline clearance is altered. It should 
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be noted that all of our PN patients were less than 16 weeks postnatal age. 
As such, the impact of PN on theophylline clearance in patients beyond 
this age could not be assessed. 
Oral formula was the primary source of nutrition in the majority of 
these patients. However, for 30% of the study patients, breast milk (typically 
supplemented with oral formula) was the major source of nutrition at some 
time during the study period. Although extreme variations in diet protein 
content have been reported to alter theophylline clearance (32), the change 
in theophylline clearance in patients who received low-protein breast milk 
feedings (with or without formula supplementation) did not differ sig- 
nificantly (p > 0.01) from the estimate of clearance in patients who received 
only oral formula. 
One of the unique aspects of this analysis was our ability to investigate 
the effects of two known inducers of drug metabolism, cigarette smoking 
and phenobarbital, on theophylline metabolism in a neonatal population. 
Although maternal cigarette smoking during pregnancy has been associated 
with placental changes and adverse fetal effects, there is no information 
concerning the distribution of polyaromatic hydrocarbons or other sub- 
stances from cigarette smoking into animal or human fetal circulation and 
their subsequent effect on fetal drug metabolism. Although smoking can 
markedly increase theophyUine clearance in adults (18,33-35), it appears 
that neonates whose mothers smoked during pregnancy do not have 
theophylline clearances significantly different than the values for neonates 
born to nonsmokers. This effect was further evaluated by performing an 
analysis that limited the effect of smoking on theophylline clearance to the 
first 2 or first 4 weeks of life. In both cases there did not appear to be a 
difference in the estimated theophylline clearance between neonates born 
to smokers or non smokers. As stated above, the maternal smoking history 
could not be ascertained for 34% of the study population. The lack of an 
effect of smoking on clearance was upheld in an analysis that assumed these 
patients were born to nonsmoking mothers and in an analysis that excluded 
these patients from the study population. 
Another possible inducer of theophylline clearance frequently used in 
this population is phenobarbital. Phenobarbital has been documented to 
induce theophylline metabolism in the adult after administration for at least 
a month, increasing theophylline clearances by 11 to 60% (36). Several 
researchers have been unable to show an effect of phenobarbital on theophyl- 
line clearance in children (37,38). However, possible induction of bilirubin 
glucuronidation in premature neonates has been achieved with only 3 to 5 
days of phenobarbital administration (39,40). During the study period, 27% 
of the patients received phenobarbital for approximately 5 days (shortly 
after birth) as prophylaxis against intraventricular hemorrhage (41). 
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Phenobarbital serum concentrations at the end of therapy were typically 
20 ~g/ml. Because the half-life of phenobarbital in this group is prolonged 
(5 to 6 days) (41), the neonate would have been exposed to significant 
serum concentrations of phenobarbital for at least a week following the 
cessation of drug therapy, and the potential effect of phenobarbital was 
allowed to be present during phenobarbital administration and for a period 
of 5 days following cessation of phenobarbital therapy. Fourteen percent 
of the theophylline serum concentrations available for analysis were 
obtained during this period. The estimated theophylline clearance in this 
group was slightly increased (12%), and although this increase was not 
statistically significant (p > 0.01), this finding may warrant further study. In 
order to pursue this further, we allowed an effect for phenobarbital in only 
those patients who received phenobarbital for more than 2 weeks. The 
estimated theophylline clearance in this small group of patients ( N = 7 )  
was also higher (10%) but not significantly different than that of similar 
patients who never received phenobarbital (p > 0.20). The small number of 
patients precludes any definitive conclusions concerning the effect of long- 
term phenobarbital administration on theophylline clearance in this 
newborn population. 
In considering the induction of theophylline clearance in neonates, it 
is important to note that the primary elimination pathways for theophylline 
in the early postnatal period include renal elimination of unchanged drug, 
hepatic microsomal methylation to caffeine, and oxidation to 1,3-dimethyl- 
uric acid probably via the cytochrome P450 system (6). Cytochrome P450 
monoxygenase, responsible for the demethylation of theophylline (a major 
route of metabolism in the adult), appears to be almost absent in the newborn 
(42). Although phenobarbital is believed to be a nonspecific inducer of the 
entire P450 system as well as other microsomal enzymes in the adult (41), 
the results of this analysis were not able to show conclusively that the P450 
pathways responsible for theophyltine metabolism in the newborn are 
significantly induced by short-term phenobarbital administration. 
One of the patient variables we examined, birth asphyxia, has been 
previously reported to result in a marked decrease in theophylline clearance. 
Gal et al. (43) originally reported a considerable decrease in theophylline 
clearance in 15 newborns (with a mean postnatal age of 10 days), in whom 
the mean theophylline clearance was 46% lower than that observed in 
nonasphyxiated newborns (10.8 vs. 20.1 ml/hr per kg). In a subsequent 
multicenter study using similar criteria, Gilman et al (17) reported a lesser 
influence of asphyxia on clearance. Newborns who had experienced birth 
asphyxia had a mean theophylline clearance that was 19% lower than 
nonasphyxiated newborns at a mean postnatal age of 14 days (16.4 vs. 
20.2 ml/hr per kg). Based on these two studies, it appears that the degree 
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to which birth asphyxia affects theophylline clearance can be very significant 
in some groups of patients but may also be quite variable. Despite the use 
of criteria for defining birth asphyxia that were similar to those of Gal (28) 
and Gilman (17), we found no significant influence of birth asphyxia on 
theophylline clearance. It may be important to note, however, that less than 
10% of our serum concentration measurements were collected within the 
first postnatal week, and any short-term change in theophylline disposition 
in subjects with birth asphyxia may not have been detected. 
Although the literature suggests that other patient factors and exposure 
to interacting medications (either in utero or postnatally) may affect 
theophylline clearance (44), the low incidence of occurrence in our study 
population precluded a study of their influence. These included in utero 
exposure to maternal medications such as cimetidine, erythromycin, 
allopurinol, phenytoin, phenobarbital, and ritodrine, postnatal exposure to 
cimetidine, erythromycin, phenytoin, and furosemide, and renal or hepatic 
dysfunction in the neonate. 
As seen in Fig. 1, theophylline clearances calculated from this study's 
results [Eq. (9)] for typical patients with postnatal ages of 1-24 weeks 
appear compatible with the mean clearances reported in traditional phar- 
macokinetic studies by other researchers for patients of similar age. With 
theophylline clearances of approximately 30ml/hr per kg at 24 weeks 
postnatal age, it appears that the patients in our population (premature 
with neonatal apnea) have not yet achieved the theophylline clearance 
values of 75-100 ml/hr per kg observed in asthmatic infants and young 
children (45). 
Compared with other drugs and other patient populations, it is surpris- 
ing that the estimate of the coefficient of variation for interindividual 
variability in theophylline clearance expressed as the coefficient of variation 
of clearance was only 16%, with a 95% confidence interval of 10.4 to 20.1%. 
These findings suggest that our final model was able to account for the 
majority of sources of interindividual variability in theophylline clearance 
in neonates and young infants. This is a much smaller degree of variability 
than observed in other newborn studies, and markedly different than the 
amount of variability observed in populations of older children and adults. 
It should be noted that because of logistical difficulties, many of the 
previously published studies in newborn patients have employed a tradi- 
tional approach to pharmacokinetic analysis to obtain individual estimates 
of pharmacokinetic parameters from limited theophylline serum concentra- 
tion determinations. The error that arises in estimating these parameters 
will add to the biologic variability and result in an inflated estimate of the 
magnitude of interindividual variability. With respect to older children and 
adults our findings underscore the importance of dietary, environmental, 
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Fig. 1. This graph depicts predicted theophylline clearances for typical patients 
receiving formula and/or breast milk feedings, or receiving parenteral nutrition. 
It illustrates the relationship between theophylline clearance (ml/hr per kg) and 
increasing postnatal age in our study population. The curves were constructed 
from estimates of theophylline clearance (ml/hr per kg) based on weight and age 
as modeled by the final clearance regression formulas. At postnatal ages of 1, 2, 
4, 8, 12, 16, 20, and 24 weeks, hypothetical patients (representative of our study 
population) were assigned body weights of 1.0, 1.0, 1.5, 2.0, 3.5, 4.0, 4.5, and 
5.0 kg, respectively. Mean clearance values for theophylline from several traditional 
pharmacokinetic studies are similarly plotted (numbers correspond to 1-9 listing 
of refs. 9-17 in Table I) for comparison. 
and genetic factors in generat ing the large degree o f  variability in theophyl-  
line disposit ion observed across these patient  populat ions.  
The estimate of  the popula t ion  mean  volume of  distribution o f  
theophyll ine (0.856 L/kg)  is similar to the range o f  values found  by others 
(see Table I): As with previous analyses o f  p redominant ly  steady state serum 
concentrat ions,  we were unable  to obtain an estimate of  the magni tude  o f  
interindividual variability in volume of  distribution (46). Much  of  the data 
for this analysis consist o f  t rough theophyll ine levels at s teady state and 
contains little informat ion regarding volume of  distribution. A more  diverse 
data set with addit ional non-steady-state  theophyl l ine concentrat ions,  con- 
centrations following loading doses, and peak concentrat ions would  have 
permitted differentiation between these two sources o f  variability. 
Seventy-two percent  o f  this s tudy's  theophyl l ine serum concentra t ion 
measurements  were collected during oral dosing regimens. Al though oral 
theophyll ine solution is reported to be highly bioavailable in adults (47), 
very little is known regarding the oral absorpt ion o f  theophyll ine in this 
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popu la t ion .  In  this analysis ,  b ioava i l ab i l i ty  of  oral  drug  was not  s ignif icant ly 
different  than  pa ren te ra l  drug,  a l though fur ther  s tudy may  be  war ran ted .  
At  a mean  theophy l l ine  serum concen t ra t ion  o f  7 p ,g /ml  obse rved  in 
this  s tudy,  the es t imate  o f  the  coefficient o f  var ia t ion  for  res idua l  var iab i l i ty  
is a p p r o x i m a t e l y  17%. This suggests a re la t ively  low a m o u n t  o f  intra-  
ind iv idua l  var iab i l i ty  in c learance .  This is pa r t i cu la r ly  no tewor thy  since the 
typ ica l  pa t i en t  in this s tudy  was fo l lowed for  a lmost  4 weeks and  had  
a p p r o x i m a t e l y  four  t heophy l l ine  serum concen t ra t ions  measured .  
C O N C L U S I O N  
Al though  the var iab i l i ty  o f  theophy l l ine  pha rmacok ine t i c s  in neona tes  
and  young  infants  is small  relat ive to that  seen in ch i ld ren  and  adul ts ,  it 
appea r s  tha t  some o f  the obse rved  var iab i l i ty  in c learance  can be  accoun ted  
for  by  the cons ide ra t ion  o f  o ther  pa t ien t  factors  b e y o n d  s imply  pa t ien t  
weight.  By mode l ing  c lea rance  with weight  ( exponen t ia l ly )  and  pos tna ta l  
age, and  inc lud ing  a fac tor  for  pat ients  receiving pa ren te ra l  nut r i t ion ,  
r ea sonab le  a pr ior i  es t imates  o f  theophy l l ine  c learance  may  be ob ta ined .  
Cl inical  app l i ca t ion  o f  these f indings to pa t i en t  care may  a l low for a more  
accura te  ini t ia l  es t imate  of  a neona te ' s  t heophy l l ine  c learance  and  for  the 
select ion o f  an a p p r o p r i a t e  ini t ial  ma in t enance  dose,  thus enabl ing  the 
c l in ic ian  to achieve a des i r ed  serum concen t ra t ion  and  a des i red  the rapeu t i c  
effect. 
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